Der Hyperadrenokortizismus gehört zu den häufigen endokrinologischen Erkrankungen des älteren Hundes. Immer wieder gibt es Unklarheiten bezüglich Art der Therapie, Therapieeinstellung und Monitoring. Diesen Fragen soll hier gemäß dem aktuellen Stand der Wissenschaft nachgegangen werden.
Georg Thieme Verlag KG Rüdigerstraße 14, 70469 Stuttgart, Germany
Literatur
1
Pérez-Alenza D,
Melián C.
Hyperadrenocorticism in Dogs. In:
Ettinger SJ,
Feldman EC,
Côté E.
Textbook of Veterinary Internal Medicine. St. Louis: Elsevier; 2017
3
Nagata N,
Kojima K,
Yuki M.
Comparison of survival times for dogs with pituitary-dependent hyperadrenocorticisim in a primary-care hospital: treated with trilostane versus untreated. J Vet Intern Med 2017; 31: 22-28
6
Kenefick SJ,
Neiger R.
The effect of trilostane treatment on circulating thyroid hormone concentrations in dogs with pituitary-dependent hyperadrenocorticism. J Small Anim Pract 2008; 49 (03) 139-143
7
McLauchlan G.
et al.
Retrospective evaluation of the effect of trilostane on insulin requirement and fructosamine concentration in eight diabetic dogs with hyperadrenocorticism. J Small Anim Pract 2010; 52: 642-648
9
Mawby DI,
Whittemore JC,
Fecteau KA.
Canine pancreatic-specific lipase concentrations in clinically healthy dogs and dogs with naturally occurring hyperadrenocorticism. J Vet Intern Med 2014; 28: 1244-1250
11
Barker EN.
et al.
A comparison of the survival times of dogs Treated with Mitotane or Trilostane for Pituitary-Dependent Hyperadrenocorticism. J Vet Intern Med 2005; 19: 810-815
12
Clemente M.
et al.
Comparison of non-selective adrenocorticolysis with mitotane or trilostane for the treatment of dogs with pituitary-dependent hyperadrenocorticism. Vet Rec 2007; 161 (24) 805-809
15
Feldman EC,
Kass PH.
Trilostane dose versus body weight in the treatment of naturally occurring pituitary-dependent hyperadrenocorticism in dogs. J Vet Intern Med 2012; 26: 1078-1080
16
Foster S.
et al.
Efficacy and safety of tightly controlled hyperadrenocorticism in dogs treated with trilostane in general practice. J Vet Intern Med 2020; 34: 3058-3166
17
Arenas Bermejo C.
et al.
Laboratory assessment of trilostane treatment in dogs with pituitary-dependent hyperadrenocorticism. J Vet Intern Med 2020; 34: 1413-1422
18
Arenas C,
Melián C,
Pérez-Alenza MD.
Evaluation of 2 trilostane protocols for the treatment of canine pituitary-dependent hyperadrenocorticism: twice daily versus once daily. J Vet Intern Med 2013; 27: 1478-1485
19
San José PG.
et al.
Changes in systolic blood pressure in dogs with pituitary dependent hyperadrenocorticism during the first year of trilostane treatment. J Vet Intern Med 2021; 35: 130-141
21
Bermejo CA.
et al.
Laboratory assessment of trilostane treatment in dogs with pituitary-dependent hyperadrenocorticism. J Vet Intern Med 2020; 34: 1413-1422
22
Griebsch C.
et al.
Effect of trilostane on hormone and serum electrolyte concentrations in Dogs with Pituitary-Dependent Hyperadrenocorticism. J Vet Int Med 2014; 28: 160-165
23
Burkhardt WA.
et al.
Adrenocorticotropic hormone, but not trilostane, causes severe adrenal hemorrhage, vacuolization, and apoptosis in rats. Domest Anim Endocrinol 2011; 40: 155-164
24
Macfarlane L,
Parkin T,
Ramsey I.
Pre-trilostane and three-hour post-trilostane cortisol to monitor trilostane therapy in dogs. Vet Record 2016.
25
Midence JN,
Drobatz KJ,
Hess RS.
Cortisol concentration in well-regulated dogs with hyperadrenocorticism treated with trilostane. J Vet Intern Med 2015; 29: 1529-1533
26
van Rijn SJ.
et al.
The influence of pituitary size on outcome after transphenoidal hypophysectomy in a large cohort of dogs with pituitary-dependent hypercortisolism. J Vet Intern Med 2016; 30: 989-995
27
Hanson JM.
et al.
Efficacy of transsphenoidal hypophysectomy in treatment of dogs with pituitary-dependent hyperadrenocorticism. J Vet Intern Med 2005; 19: 687-694
29
Arenas C,
Melián C,
Pérez-Alenza MD.
Long-term survival of dogs with adrenal-dependent hyperadrenocorticism: a comparison between mitotane and twice daily trilostane treatment. J Vet Intern Med 2014; 28: 473-480